InsiderTrades

Form 4 for APUS Apimeds Pharmaceuticals US, Inc.

Accepted 2025-05-14 00:00:00 ET · period of report 2025-05-12 · accession 0001474506-25-000089 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-05-14 2025-05-12 APUS Inscobee Inc. 10% C - Cnv Deriv $2.60 +44.0K 2.03M +2% +$114.5K
DMI 2025-05-14 2025-05-12 APUS Inscobee Inc. 10% C - Cnv Deriv $2.60 +253.1K 4.32M +6% +$658.0K
D 2025-05-14 2025-05-12 APUS Inscobee Inc. 10% P - Purchase $4.00 +500.0K 1.98M +34% +$2.00M
DMI 2025-05-14 2025-05-12 APUS Inscobee Inc. 10% C - Cnv Deriv — 0 0 New —
D 2025-05-14 2025-05-12 APUS Inscobee Inc. 10% C - Cnv Deriv — 0 0 New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock, par value $0.01 per share 2025-05-12 C A 44,041 $2.60 2,028,657 D — —
2 Common Common Stock, par value $0.01 per share 2025-05-12 C A 71,090 $2.60 4,387,708 I — — (F3) The shares of common stock are owned directly by Apimeds Korea, which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
3 Common Common Stock, par value $0.01 per share 2025-05-12 C A 182,002 $2.60 4,316,618 I By Apimeds Inc. — — (F3) The shares of common stock are owned directly by Apimeds Korea, which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
4 Common Common Stock, par value $0.01 per share 2025-05-12 P A 500,000 $4.00 1,984,616 D By Apimeds Inc. — — (F3) The shares of common stock are owned directly by Apimeds Korea, which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
5 Derivative Convertible Promissory Note 2025-05-12 C D — $0.00 0 I By Apimeds Inc. $2.60 · — to — 71,090 Common Stock, par value $0.01 per share (F3) The shares of common stock are owned directly by Apimeds Korea, which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. (F4) On March 21, 2022, the Issuer issued to Apimeds Korea a convertible promissory note in the principal amount of $160,000 (as amended, the "March 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the March 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The March 2022 Note bears interest at an annual rate of 5%. The March 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $160,000, plus $24,833 of accrued and unpaid interest.
6 Derivative Convertible Promissory Note 2025-05-12 C D — $0.00 0 I By Apimeds Inc. $2.60 · — to — 182,022 Common Stock, par value $0.01 per share (F3) The shares of common stock are owned directly by Apimeds Korea, which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. (F1) On August 30, 2021, Apimeds Pharmaceuticals US, Inc. (the "Issuer") issued to Apimeds Inc. ("Apimeds Korea") a convertible promissory note in the principal amount of $400,000 (as amended, the "August 2021 Note"). All outstanding principal and accrued and unpaid interest owed under the August 2021 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of an offering of the Issuer's common stock resulting in the listing of the Issuer's common stock on the NYSE American, or other national securities exchange (a "Qualified Offering"). The August 2021 Note bears interest at an annual rate of 5%. The August 2021 Note is convertible into shares of common stock at a conversion price of $2.60 per share (the "Conversion Price"). The amount reported in Column 3 of Table II represents the original principal amount of $400,000, plus $73,205 of accrued and unpaid interest.
7 Derivative Convertible Promissory Note 2025-05-12 C D — $0.00 0 D $2.60 · — to — 44,041 Common Stock, par value $0.01 per share (F5) On June 3, 2022, the Issuer issued to Inscobee Inc. a convertible promissory note in the principal amount of $100,000 (as amended, the "June 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the June 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The June 2022 Note bears interest at an annual rate of 5%. The June 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $100,000, plus $14,507 of accrued and unpaid interest.